PharmaGap Inc.  

(Public, CVE:GAP)   Watch this stock  
Find more results for Dan Leahy
0.005
Delayed:   1:13PM EDT
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.00 - 0.00
Open     -
Vol / Avg. 0.00/0.00
Mkt cap 728,145.00
P/E     -
Div/yield     -
EPS -0.02
Shares     -
Beta 0.58
Inst. own     -

Key stats and ratios

Q3 (Sep '12) 2011
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -816.54% -810.47%
Return on average equity - -
CDP Score - -

Address

100 Sussex Drive
Ottawa, ON K1A 0R6
Canada
+1-613-9983400 (Phone)
+1-613-9983399 (Fax)

Website links

Description

PharmaGap Inc. (PharmaGap) is a development-stage company. The Company is principally engaged in drug development and out-licensing of drug compounds. The Company is focused on the development of novel drugs for treatment of cancer and other human disease conditions. PharmaGap´┐Żs lead drug compound, GAP-107B8, is in the pre-clinical testing stage and has shown in vitro and in vivo efficacy in selected cancer types. During the year ended December 31, 2011, the Company commenced specific programs to further elucidate information regarding the pharmacokinetics and toxicity profiles of GAP-107B8. A program to develop liposomal delivery formulations of GAP-107B8 in order to optimize the delivery and safety of the drug compound was completed during 2011. The Company is developing GAP-107B8 for first clinical trials in ovarian cancer, using the intra-peritoneal route of administration.

Officers and directors

Roderick M. Bryden Chairman of the Board
Age: 72
Robert C. McInnis President, Chief Executive Officer
Gerald Leahy Chief Financial Officer
Kenneth K. Sokoll Ph.D. Chief Operating Officer
Jenny Phipps Chief Scientific Officer, Director
Daniel B. Larkin Independent Director
Robert Letellier Independent Director
Ian W. Malone Independent Director